Showing 891-900 of 2371 results for "".
- Update on Migraine Incidence and Risk for Progression from Episodic to Chronic Migrainehttps://practicalneurology.com/news/update-on-migraine-incidence-of-migraine-and-risk-for-progression-from-episodic-to-chronic-migraine/2469439/At the Virtual Scottsdale Headache Symposium 2020, Richard Lipton, MD presented the latest data from epidemiology studies of migraine. Dr. Lipton noted that epidemiologic studies not only provide a conceptual model of the disease and approaches for better understanding but also help to assess and
- Posttraumatic Headache Management Update from Virtual Scottsdale Headache Symposium 2020https://practicalneurology.com/news/posttraumatic-headache-management-update-from-virtual-scottsdale-headache-symposium-2020/2469438/At the Virtual Scottsdale Headache Symposium 2020 held on November 21st, 2020, Dr. Juliana VanderPluym, MD, FAHS of the Mayo clinic reviewed current knowledge on management of posttraumatic headache, providing a step-by-step approach as follows below. 1. Posttraumatic headache is
- Teens with Epilepsy Are More Likely to Discuss Suicide Onlinehttps://practicalneurology.com/news/teens-with-epilepsy-are-more-likely-to-discuss-suicide-online/2469098/Results of a study presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD show that teens with epilepsy are more than twice as likely as adults with the condition to talk about suicide online. The data suggests that teens are concerned with the unknown aspe
- Women with Epilepsy Are Less Likely to Breastfeed Their Newbornshttps://practicalneurology.com/news/women-with-epilepsy-are-less-likely-to-breastfeed-their-newborns/2469096/Findings from 2 clinical studies presented at the American Epilepsy Society Annual Meeting, December 6-10 in Baltimore, MD show that women with epilepsy are less likely to breastfeed their newborns than new mothers without epilepsy. Support from neurologists and lactation consultants, however, ca
- Database of Eye-Tracking Movements Could Aid Diagnosis and Treatmenthttps://practicalneurology.com/news/database-of-eye-tracking-movements-could-aid-diagnosis-and-treatment/2468784/Eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) that captures data on people’s eye movements has been used to produce a database of 1 billion data points from 100,000 individuals. Data includes eye tracking measures of alignment, object tracking, depth perception, and dy
- FDA Provides Expanded Clearance for Device to Treat Migraine in Childrenhttps://practicalneurology.com/news/fda-provides-expanded-clearance-for-device-to-treat-migraine-in-children/2468822/The Food and Drug Administration (FDA) has granted new marketing clearance for a device that provides acute and preventive treatment of migraine to include children 12 years of age and older. The technology (sTMS; eNeura, Inc., Baltimore, MD) is a non-invasive device that uses single-puls
- New Guidelines Issued for Gene Therapy Treatment in Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/new-guidelines-issued-for-gene-therapy-treatment-in-duchenne-muscular-dystrophy/2483121/The Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) have jointly published consensus guidelines on the safe and equitable administration of gene therapy for Duchenne muscular dystrophy (DMD) in Neuromuscular Disorders. The recommendations provide neurolo
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- FDA Approves Neonatal Fc Receptor Blocker Treatment for Individuals with Generalized Myasthenia Gravishttps://practicalneurology.com/news/fda-approves-neonatal-fc-receptor-blocker-treatment-for-individuals-with-generalized-myasthenia-gravis/2474395/The Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab; Johnson & Johnson, New Brunswick, NJ) for the treatment of individuals aged >12 years with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK)
- Diagnosis and Care Recommendations for Limb-Girdle Muscle Dystrophy 2I/R9 Presentedhttps://practicalneurology.com/news/diagnosis-and-care-recommendations-for-limb-girdle-muscle-dystrophy-2ir9-presented/2473813/Draft standard of care (SoC) guidelines for the diagnosis and management of people with limb-girdle muscle dystrophy 2I/R9 (LGMDR9) were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. According to the presenters of the draft SoC, the guidelines ar